MYC需要MNT协同驱动B细胞恶性转化
本文为Blood期刊评论文章,围绕Nguyen等在同期发表的研究展开解读。该研究基于Cory团队此前发现的MYC与MNT在肿瘤性B细胞发育中的协同作用,进一步阐明其机制,并将MNT鉴定为治疗和预防MYC依赖型B细胞肿瘤(如非霍奇金淋巴瘤和多发性骨髓瘤)的潜在分子靶点。
要点
- MNT与MYC:MAX二聚体竞争结合基因启动子,发挥转录拮抗作用。
- MNT对MYC致癌潜力的增强或削弱取决于细胞类型和生物学背景。
- MNT被鉴定为MYC依赖型B细胞肿瘤的潜在治疗与预防靶点。
核心结论
- MNT是治疗和预防MYC依赖型B细胞肿瘤(如非霍奇金淋巴瘤和多发性骨髓瘤)有前景的分子靶点。
研究设计与样本
- 本文为Blood期刊评论文章,解读Nguyen等针对Cory团队此前发现的MYC与MNT协同作用机制开展的后续研究。
主要发现
- MNT与MYC的相互作用超越转录拮抗,调控多种发育通路和细胞命运决定。
- MNT可根据细胞类型和生物学背景增强或削弱MYC的致癌潜力。
- Nguyen等的研究填补了MYC与MNT在肿瘤性B细胞发育中协同作用机制的空白。
临床怎么用
- MNT可作为MYC依赖型B细胞肿瘤治疗与预防的候选分子靶点,但尚需进一步临床验证。
局限性
- 本文为评论文章,未报告原始研究的具体样本量、数值和统计结果。
- 异常MYC表达目前仍难以实现治疗性靶向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
MNT is a member of the MYC transcription factor network of proteins that must heterodimerize with MYC-associated factor X, or MAX for short, to bind certain DNA recognition motifs in gene promoters that regulate gene expression. Because many target genes that are activated by MYC:MAX dimers are repressed by MNT:MAX dimers, MNT is considered a transcriptional antagonist of MYC. However, the interaction of MNT and MYC goes further, beyond transcriptional antagonism, and governs a multitude of developmental pathways and cell fate decisions that include MNT’s ability to fortify or weaken MYC’s oncogenic potential depending on cell type and biological context. Previous work by Cory’s group pointed to a synergistic interaction of MYC and MNT in neoplastic B-cell development, but the underlying mechanism remained unclear. In this issue of Blood, Nguyen et al have now addressed this knowledge gap with a follow-up study that identified MNT as a promising molecular target for the treatment and prevention of MYC-dependent B-cell neoplasms such as non-Hodgkin lymphoma and multiple myeloma. This is significant because at this juncture aberrant MYC expression stubbornly resists any attempt at therapeutic targeting.
引用
- Janz S. MYC needs MNT to drive B cells over the edge. Blood. 2020. PMID: 32219348. doi:10.1182/blood.2019004766
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。